|drug2264||Norovirus Bivalent (GI.1 / GII.4) Vaccine（middle） Wiki||1.00|
|drug218||Aluminum adjuvant Wiki||1.00|
|drug2262||Norovirus Bivalent (GI.1 / GII.4) Vaccine（high） Wiki||1.00|
|D017250||Caliciviridae Infections NIH||0.71|
There is one clinical trial.
A total of 450 subjects were enrolled, divided into four age groups, including 18-59 years, 6-17 years, 3-5 years, and 6-35 months. There are three types of the test vaccine component in each age group. A total of 30 people in each dose group were vaccinated with the test vaccine or placebo 1 or placebo 2, respectively, in a ratio of 3: 1: 1. The 18-59-year-old, 6-17-year-old, and 3-5-year-old age groups were vaccinated 2 times at a time interval of 28 days. The 6-35 month age group is divided into two groups, Group 1 is inoculated with 2 doses interval of 28 days each, and Group 2 is inoculated with 3 doses interval of 28 days.
Description: Active AE: Local and systemic adverse reactions occurring within 0-7 days after each dose of vaccinationMeasure: All active AEs within 0-7 days after each dose Time: 7 days
Description: Adverse events other than active AE include solicitation adverse events reported in addition to the specified solicitation time windowMeasure: All non-active collection AEs within 0-28（30） days after each dose Time: 28（30） days
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports